790 related articles for article (PubMed ID: 30282887)
1. Impact of the modification of the diagnostic criteria in the 2017 Bethesda System for Reporting Thyroid Cytopathology: a report of a single institution in Japan.
Higuchi M; Hirokawa M; Kanematsu R; Tanaka A; Suzuki A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1193-1198. PubMed ID: 30282887
[TBL] [Abstract][Full Text] [Related]
2. Implementing noninvasive follicular thyroid neoplasm with papillary-like nuclear features may potentially impact the risk of malignancy for thyroid nodules categorized as AUS/FLUS and FN/SFN.
Li W; Sciallis A; Lew M; Pang J; Jing X
Diagn Cytopathol; 2018 Feb; 46(2):148-153. PubMed ID: 29193839
[TBL] [Abstract][Full Text] [Related]
3. Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules.
Strickland KC; Howitt BE; Barletta JA; Cibas ES; Krane JF
Cancer Cytopathol; 2018 Feb; 126(2):86-93. PubMed ID: 28914983
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
[TBL] [Abstract][Full Text] [Related]
5. High risk of malignancy in cases with atypia of undetermined significance on fine needle aspiration of thyroid nodules even after exclusion of NIFTP.
Özkara SK; Bayrak BY; Turan G
Diagn Cytopathol; 2020 Nov; 48(11):986-997. PubMed ID: 32745375
[TBL] [Abstract][Full Text] [Related]
6. Did Introducing a New Category of Thyroid Tumors (Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features) Decrease the Risk of Malignancy for the Diagnostic Categories in the Bethesda System for Reporting Thyroid Cytopathology?
Kopczyński J; Suligowska A; Niemyska K; Pałyga I; Walczyk A; Gąsior-Perczak D; Kowalik A; Hińcza K; Mężyk R; Góźdź S; Kowalska A
Endocr Pathol; 2020 Jun; 31(2):143-149. PubMed ID: 32236858
[TBL] [Abstract][Full Text] [Related]
7. Hürthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology.
Yazgan A; Balci S; Dincer N; Kiyak G; Tuzun D; Ersoy R; Cakir B; Guler G
Cytopathology; 2014 Jun; 25(3):185-9. PubMed ID: 24024935
[TBL] [Abstract][Full Text] [Related]
8. The influence of the reclassification of NIFTP as an uncertain tumour on risk of malignancy for the diagnostic categories according to the Bethesda system for reporting thyroid cytopathology.
Kopczyński J; Suligowska A; Niemyska K; Palyga I; Walczyk A; Gąsior-Perczak D; Kowalik A; Hińcza K; Mężyk R; Góźdź S; Kowalska A
Endokrynol Pol; 2019; 70(3):232-236. PubMed ID: 30845342
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review and Meta-analysis of the Impact of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Cytological Diagnosis and Thyroid Cancer Prevalence.
Ruanpeng D; Cheungpasitporn W; Thongprayoon C; Hennessey JV; Shrestha RT
Endocr Pathol; 2019 Sep; 30(3):189-200. PubMed ID: 31338752
[TBL] [Abstract][Full Text] [Related]
10. RISK OF MALIGNANCY IN THYROID CYTOLOGY: THE IMPACT OF THE RECLASSIFICATION OF NONINVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES (NIFTP).
Ventura M; Melo M; Fernandes G; Carrilho F
Endocr Pract; 2019 Jul; 25(7):642-647. PubMed ID: 30865528
[No Abstract] [Full Text] [Related]
11. The importance of risk of neoplasm as an outcome in cytologic-histologic correlation studies on thyroid fine needle aspiration.
Chen YH; Partyka KL; Dougherty R; Cramer HM; Wu HH
Diagn Cytopathol; 2020 Dec; 48(12):1237-1243. PubMed ID: 32716614
[TBL] [Abstract][Full Text] [Related]
12. Cytopathology of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: A comparative study with similar patterned papillary thyroid carcinoma variants.
Mahajan S; Agarwal S; Kocheri N; Jain D; Mathur SR; Iyer VK
Cytopathology; 2018 Jun; 29(3):233-240. PubMed ID: 29638022
[TBL] [Abstract][Full Text] [Related]
13. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B
Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595
[TBL] [Abstract][Full Text] [Related]
14. Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated Follicular Variant Papillary Thyroid Carcinomas to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Jeon MJ; Song DE; Jung CK; Kim WG; Kwon H; Lee YM; Sung TY; Yoon JH; Chung KW; Hong SJ; Baek JH; Lee JH; Kim TY; Shong YK; Kim WB
PLoS One; 2016; 11(12):e0167756. PubMed ID: 27936121
[TBL] [Abstract][Full Text] [Related]
15. CLINICAL IMPACT OF NON-INVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES ON THE RISK OF MALIGNANCY IN THE BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: A META-ANALYSIS OF 14,153 RESECTED THYROID NODULES.
Vuong HG; Tran TTK; Bychkov A; Jung CK; Nakazawa T; Kakudo K; Katoh R; Kondo T
Endocr Pract; 2019 May; 25(5):491-502. PubMed ID: 30657357
[No Abstract] [Full Text] [Related]
16. Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Is Not a Cytological Diagnosis, but It Influences Cytological Diagnosis Outcomes: A Systematic Review and Meta-Analysis.
Haaga E; Kalfert D; Ludvíková M; Kholová I
Acta Cytol; 2022; 66(2):85-105. PubMed ID: 34781293
[TBL] [Abstract][Full Text] [Related]
17. Impact of the 3rd Edition of the Bethesda System for Reporting Thyroid Cytopathology on Grey Zone Categories.
Guerreiro SC; Tastekin E; Mourao M; Loureiro I; Eusebio R; Marques HP; Oznur M; Caliskan CK; Schmitt FC; Bongiovanni M; Canberk S
Acta Cytol; 2023; 67(6):593-603. PubMed ID: 37899024
[TBL] [Abstract][Full Text] [Related]
18. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
19. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
20. Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: Experience of a Tertiary Care Referral Center.
Heider A; Arnold S; Jing X
Arch Pathol Lab Med; 2020 Apr; 144(4):473-477. PubMed ID: 31403334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
